Call for expressions of interest (EOI) from test developers for rapid point-of-care tests for the detection of prognostic biomarkers of severity for SARS-CoV-2 infections

BACKGROUND
FIND is a global non-profit organization dedicated to accelerating the development, evaluation, and delivery of high-quality, affordable diagnostic tests for poverty-related diseases. FIND is partnering with humanitarian and academic stakeholders to identify prognostic markers of severity in adults with non-severe COVID-19, with a focus to aid safe discharge from a healthcare facility (i.e. with a high negative predictive value [NPV]).

The purpose of this EOI is to solicit researchers/commercial companies developing tests for the detection of prognostic biomarkers of severity for SARS-CoV-2 infections. This will inform FIND’s landscape of available diagnostic tests or tests that might become commercially available within one year (fully integrated and preliminary studies with clinical samples completed). (►TLR 4).

OBJECTIVES
The objectives of this call are:
- Update the landscape of available tests for prognostic biomarkers of severity for SARS-CoV-2 infections
- Gauge interest among test developers to participate in a study
- Include promising tests in a comparative assessment study to commence within the next month

FIND is particularly interested in tests with previously published methods, data supporting performance for prognosis of SARS-CoV-2 infections, tests that are likely to be commercially available within one year, and tests that can be performed in settings with limited infrastructure (power supply, temperature control for example). Assays with previous data from low- and middle-income countries (LMICs) for prognosis in the context of respiratory infections or sepsis are prioritized.

BENEFITS OF WORKING WITH FIND
- FIND will support procurement of commercially available tests, where relevant
- Potential access to investment and collaborations beyond this study
- Early access to field sites for short term, targeted feasibility testing
- Benefiting from FIND’s technical and global health expertise
- Potential to reduce morbidity and mortality in LMICs from COVID-19 and beyond

TIMELINES
- Expression of interest and completion of the company and technology questionnaire (including analytical performance data) is to be submitted by 15 June 2020. The questionnaire is also provided through a separate link on the Calls for partners page.
- Submission review and due diligence will be performed by FIND staff. FIND staff will contact applicants in case of any questions and confirm interest in test evaluation.

Conditions
Where developers consider there is information that needs to remain confidential, FIND can provide its standard Mutual Non-disclosure Agreement for execution.

SEND SUBMISSIONS BEFORE 15 June 2020 TO: RFP_MF@finddx.org

FOR QUESTIONS or SUBMISSION, CONTACT: RFP_MF@finddx.org